This is a match-making section for OHAMR Call for proposals 2026.
H - Human Health
antimicrobial nanostructures; biologically produced nanoparticles; co-culture cytocompatibility assays; modified drug nanocarriers
We are a fully equipped independent biomedical unit formed recently by professionals with broad experience in molecular biology, microbiology, and cell biology techniques, as well as in publishing and (inter)national proposal preparation. We perform progressive methods of cell culture co-cultivation, biocompatibility tests, gene expression analyses, as well as surface and intracellular analyses of particular molecules. Our main research focus is characterization of nano-bio interaction and application of nanomaterial in theragnostic, daily-use products, and environmental challenges. Being part of the Liberec Technical University, leading institution in nanofiber development, we have a strategic role between nanomaterial production and its practical application or clinical trials. We collaborate with top clinical sites and hospitals, giving us firsthand insight into real healthcare environments, including standard care, intensive care units, surgical departments, and more. Pathologies we are aiming for (but not limited to) are neurodegenerative diseases, skin disturbances, and solid tumors.
We seek partnership with other research groups to work on development, characterization, and possible application of a variety of nanomaterials to address modern human needs and to face human pathologies or environmental challenges.Potential topics for collaboration can involve testing/development of modified drug nanocarriers, bio-nanoparticles, or enriched nanostructured surfaces suitable as implants or drug scaffolds. Within OHAMR call 2026 we are seeking a partner / coordinator who would join us with a project on alternative antimicrobials development and testing. We offer 1) testing of newly developed materials in human cell lines, primary blood cells, freshly collected microbial populations from different sites in health care system (emergency units, standard units etc.) or 2) development biogenic nanoparticles as ATB alternatives or modifiers and their testing within different pathologies. We are also fully open to other areas within the exploration of nano-bio interaction too.
Submitted on 2025-12-04 15:00:06
« Return to the partner search tool